5 results about "Hsp90" patented technology

This invention relates to a compound based on CRBN ligand-induced ubiquitination degradation of Hsp90, its preparation method and uses, as shown in X-Y-Z, where X represents the ligand of HSP90 protein, Z represents the ligand of E3 ligase, and Y represents the chain connecting X and Z. This type of compound can be used to treat or prevent tumors.

The expression of the ATXN2 gene can be modulated to reduce the amount of ataxin-2 protein produced by a cell. This can be accomplished by administering to the cell an effective amount of an ATXN2 modulating agent. Screening was performed with 428,749 compounds for lowering expression of an ATXN2-luciferase reporter in HEK-293 cells, with a multiplexed cell viability assay to ensure target reduction in the absence of cytotoxicity. Secondary qHTS assays included a CMV-luciferase reporter expressed in HEK-293 cells as well as a biochemical assay using recombinant luciferase to detect inhibitors of the reporter enzyme. A diverse set of compounds were found to reduce ATXN2 expression, including compounds targeting HSP90, cardiac glycosides, NaK-ATPases and topoisomerases.

This application relates to a cyanobacteria extract with photothermal damage repair effects, its preparation method, and its application, belonging to the field of cosmetic raw material technology. The cyanobacteria extract provided in this application can be used to balance the inflammatory and repair signaling pathways of skin cells after photothermal damage, and can be used to prepare skin care products with soothing, anti-inflammatory, and barrier-repair-promoting effects. It can synergistically balance the pro-inflammatory damage signaling pathway TLR4 / NF-κB axis and the survival-promoting repair signaling pathway HSP90 / PI3K-Akt axis simultaneously activated in skin cells after photothermal damage, targeting multiple points. This can more effectively control excessive inflammation, reduce secondary damage, and enhance the cell's self-repair ability. It is suitable for various scenarios such as sunburn, post-laser surgery, and thermal environment damage, and has significant technical advantages compared to existing technologies, with broad application prospects and huge market value.

The present invention relates to: a chromene-benzimidazole derivative or a pharmaceutically acceptable salt thereof; and a composition for preventing or treating cancer, the composition comprising the derivative as an active ingredient. The chromene-benzimidazole derivative according to the present invention is activated in cancer cells to inhibit tubulin polymerization and suppress the C-terminal domain of Hsp90, thereby blocking the cell cycle of cancer cells, inducing apoptosis, and inhibiting the activity of oncoproteins, and thus can be used as a novel dual-target anticancer drug for preventing or treating cancer, preferably for preventing or treating triple-negative breast cancer.

The present application relates to the technical field of radiopharmaceuticals, and discloses a polypeptide compound targeting HSP90, a radioactive probe labeling precursor, a radioactive probe and a preparation method and application thereof, wherein a polypeptide compound targeting HSP90 is obtained by screening a polypeptide specifically combined with HSP90 from a T7 phage display polypeptide library; the polypeptide compound targeting HSP90 is synthesized, and is subjected to a coupling reaction by being mixed with a linking arm and a chelating agent to obtain a crude product of a labeling precursor, and after purification, a radioactive probe labeling precursor targeting HSP90 is obtained; a nuclide eluent is eluted, and then is mixed with the radioactive probe labeling precursor targeting HSP90, and after incubation, a radioactive probe targeting HSP90 is obtained. The radioactive molecular probe prepared by the present application can be specifically combined with HSP90 protein, has high affinity and functional activity for HSP90, and can evaluate the expression level of HSP90 in real time in vivo.